PFE
Pfizer Inc. · Healthcare · Drug Manufacturers - General
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 12.33M | $340.69M | n/a | n/a |
| Q2 2026 | 175 | +3 | 3.07B | $73.85B | +7 | −3 |
| Q1 2026 | 174 | -2 | 3.01B | $84.42B | +3 | −6 |
| Q4 2025 | 175 | 0 | 3.18B | $79.18B | +2 | −1 |
| Q3 2025 | 25 | -1 | 1.84B | $46.80B | +1 | −3 |
| Q2 2025 | 24 | -1 | 1.79B | $43.32B | n/a | −1 |
| Q1 2025 | 22 | +1 | 777.51M | $19.69B | +2 | −1 |
| Q4 2024 | 21 | +2 | 779.18M | $20.66B | +2 | n/a |
| Q3 2024 | 18 | -2 | 507.62M | $14.68B | n/a | −2 |
| Q2 2024 | 20 | n/a | 545.09M | $15.24B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Assenagon Asset Management S.A. | 7.51M | -68.4% | $214.33M | 0.2% | ▼ Trim | 4 | SEC ↗ |
| 2 | Wealth Enhancement Advisory… | 4.13M | +30.8% | $107.03M | 0.2% | ▲ Add | 4 | SEC ↗ |
| 3 | TD Waterhouse Canada Inc. | 686.97K | +2.1% | $19.33M | 0.1% | ▲ Add | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 225.90K shares, $6,343 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Officer, Director · Chairman & CEO · 38.00K sh @ 26.34 · $1.00M
Open-market sales (S)
No open-market insider sales in our coverage window.
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology